Keratoacanthoma (KA): An update and review - 15/05/16
Abstract |
Keratoacanthoma (KA) is a common but underreported tumor of the skin. Two striking features of KA are its clinical behavior with spontaneous regression after rapid growth and its nosological position on the border between benignity and malignancy. We review current knowledge on the clinical, histopathological, and dermoscopic features of KA to ensure a proper diagnosis and describe its variants, including different types of multiple KAs. We highlight current concepts of KA ethiopathogenesis with special emphasis on the genetic background of multiple familial KA, the role of Wnt signaling pathway, and induction of KA by BRAF inhibitors and procedures of esthetic dermatology. Finally, treatment strategies are presented with surgical excision as a first option, followed by other modalities, including intralesional chemotherapy, topical and systemic agents, lasers, cryotherapy, and photodynamic therapy.
Le texte complet de cet article est disponible en PDF.Key words : BRAF inhibitor, erlotinib, Ferguson-Smith, Grzybowski, histopathology, keratoacanthoma, multiple keratoacanthoma, multiple self-healing squamous epithelioma, squamous cell carcinoma, treatment
Abbreviations used : GEKA, KA, MSHSE, MTS, SCC
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 74 - N° 6
P. 1220-1233 - juin 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?